Release Date: 01/11/17 08:18 Summary: Announces Q3 2017 Operating and Financial Results Price Sensitive: Yes Download Document 191.11KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%